改良抗血小板药物方案在血小板高反应性未破裂颅内动脉瘤患者介入栓塞中的疗效及安全性

doi:10.3969/j.issn.1006-7795.2018.01.025

首都医科大学学报 ›› 2018, Vol. 39 ›› Issue (1): 143-147.doi: 10.3969/j.issn.1006-7795.2018.01.025

改良抗血小板药物方案在血小板高反应性未破裂颅内动脉瘤患者介入栓塞中的疗效及安全性

夏鹏飞^1,2, 王伟¹, 邹亮¹, 马英明¹

1. 内蒙古民族大学第二临床医学院神经外科, 内蒙古牙克石 022150;
2. 内蒙古民族大学, 内蒙古通辽 028000

收稿日期:2017-04-13 出版日期:2018-01-21 发布日期:2018-01-27
通讯作者: 王伟 E-mail:18647001117@163.com

Efficacy and safety of modified antiplatelet preparation in patients with high on-treatment platelet reactivity after endovascular coiling for unruptured intracranial aneurysms

Xia Pengfei^1,2, Wang Wei¹, Zou Liang¹, Ma Yingming¹

1. Department of Neurosurgery, The Second Clinical Medical School of Inner Mongolia University for the Nationalities, Yakeshi 022150, Inner Mongolia Autonomous Region, China;
2. Department of Inner Mongolia University, TongLiao 028000, Inner Mongolia Autonomous Region, China

Received:2017-04-13 Online:2018-01-21 Published:2018-01-27

摘要/Abstract

摘要： 目的评价改良抗血小板药物方案在有血小板高反应性（high on-treatment platelet reactivity，HTPR）的颅内未破裂动脉瘤（unruptured intracranial aneurysms，UIA）患者介入栓塞中的疗效和安全性。方法采取随机平行对照的方法连续入选有HTPR的UIA患者166例，行血管内介入治疗术，并根据抗血小板药物剂量分为标准剂量组（给予阿司匹林100 mg 1次/d+氯吡格雷75 mg 1次/d（n=83）]及修改剂量组[给予阿司匹林300 mg 1次/d+氯吡格雷75 mg 1次/d或阿司匹林100 mg 1次/d+氯吡格雷75 mg 1次/d+西洛他唑100 mg 2次/d（n=83）]，疗程为3个月。采用3种方法多时点的检测血小板功能。比较两组患者脑梗死和血管内血栓形成等不良缺血事件和出血事件的发生率。结果修改剂量组在各时点的血小板反应性均低于标准剂量组，且差异有统计学意义；修改剂量组较标准剂量组不良缺血事件发生率显著降低，差异有统计学意义（8.4%vs 1.2%，HR=0.132，95% CI 0.016~1.101，P=0.030）；修改剂量组出血事件发生率高于标准剂量组，但差异无统计学意义。结论修改剂量抗血小板方案可以在不增加出血事件发生率的情况下降低有HTPR的UIA患者介入术后不良缺血事件的发生。

关键词: 颅内未破裂动脉瘤, 介入治疗, 高剂量, 抗血小板, 疗效, 安全性

Abstract: Objective To evaluate the efficacy and safety of modified antiplatelet preparation in patients with high on-treatment platelet reactivity(HTPR) after endovascular coiling for unruptured intracranial aneurysms(UIA).Methods In the randomized, parallel designed clinical trial, 166 patients colling for UIA with HTPR were assigned to receive either 100 mg of aspirin and 75 mg of clopidogrel bisulfate once daily for 3 months(n=83) or 300 mg of aspirin and 75 mg of clopidogrel bisulfate once daily, or 100 mg of aspirin and 75 mg of clopidogrel bisulfate once daily and cilostazol twice daily for 3 months(n=83). Platelet function was serially measured at various time points by 3 assessment methods. Adverse ischemia events(stroke and intravascular thrombosis) and bleeding events were evaluated.Results Patients with HTPR was fewer in modified group compared with standard group at various time points. The adverse ischemia events occurred in fewer patients in modified group than in standard group(8.4% vs 1.2%,HR=0.132,95% CI:0.016-1.101,P=0.030). There was no statistical difference in the rate of bleeding events between modified group and standard group.Conclusion Modified antiplatelet preparation for patients with HTPR compared with standard antiplatelet preparation reduced the adverse ischemia events rate in coiling for an unruptured aneurysm without increasing bleeding.

Key words: unruptured intracranial aneurysms (UIA), interventional therapy, high-dose, antiplatelet, efficacy, safety

中图分类号:

R739.41

夏鹏飞, 王伟, 邹亮, 马英明. 改良抗血小板药物方案在血小板高反应性未破裂颅内动脉瘤患者介入栓塞中的疗效及安全性[J]. 首都医科大学学报, 2018, 39(1): 143-147.

Xia Pengfei, Wang Wei, Zou Liang, Ma Yingming. Efficacy and safety of modified antiplatelet preparation in patients with high on-treatment platelet reactivity after endovascular coiling for unruptured intracranial aneurysms[J]. Journal of Capital Medical University, 2018, 39(1): 143-147.

参考文献

[1] Pierot L, Wakhloo A K. Endovascular treatment of intracranial aneurysms:current status[J]. Stroke, 2013, 44(7):2046-2054.
[2] Hong Y, Wang Y J, Deng Z, et al. Stent-assisted coiling versus coiling in treatment of intracranial aneurysm:a systematic review and meta-analysis[J]. PLoS One, 2014, 9(1):e82311.
[3] Chalouhi N, Jabbour P, Singhal S, et al. Stent-assisted coiling of intracranial aneurysms:predictors of complications, recanalization, and outcome in 508 cases[J]. Stroke, 2013, 44(5):1348-1353.
[4] 中华预防医学会卒中预防与控制专业委员会介入学组. 缺血性脑血管病介入治疗抗血小板策略中国专家共识[J]. 中华医学杂志, 2015, 95(11):803-809.
[5] Tantry U S, Bonello L, Aradi D, et, al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding[J]. J Am Coll Cardiol, 2013, 62(24):2261-2273.
[6] 吴长鸿,刘斌.第四届全国脑血管病学术会议[J].中华医学信息导报,1996;29(6):376-381.
[7] Liu J, Xu Z Q, Cui M, et al.Assessing risk factors for major adverse cardiovascular and cerebrovascular events during the perioperative period of carotid angioplasty with stenting patients[J].Exp Ther Med, 2016, 12(2):1039-1047.
[8] Zammar S G, Hamade Y J, El Ahmadieh T Y, et, al. Pitfalls and complications management in the endovascular treatment of aneurysms[J]. Neurosurg Clin N Am, 2014, 25(3):405-413.
[9] Seadon S, Lang E. Clopidogrel with aspirin versus aspirin alone in prevention of stroke following transient ischemic attack or acute minor stroke[J]. CJEM, 2015, 17(3):315-317.
[10] Lin L, Wang H, Chen Y F, et, al. High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention:a meta-analysis[J]. Oron Artery Dis, 2015, 26(5):386-395.
[11] Aradi D, Storey R F, Komocsi A, et, al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention[J]. Eur Heart J, 2014, 35(4):209-215.
[12] Floyd C N, Ferro A. Mechanisms of aspirin resistance[J]. Pharmacol Ther, 2014, 141(1):69-78.
[13] Le Quellec S, Bordet J C, Negrier C, et, al. Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature[J]. Thromb Haemost, 2016, 116(4):638-650.
[14] 唐蕊,赵明哲,庄向阳,等.阿司匹林联合小剂量氯吡格雷治疗75岁以上急性脑梗死临床效果观察[J].临床误诊误治,2015,28(8):85-88.
[15] Du G, Lin Q, Wang J. A brief review on the mechanisms of aspirin resistance[J]. Int J Cardiol, 2016,220:21-26.
[16] Wehbeh A, Rochey D C, Barada K, et, al. Risks of bleeding recurrence and cardiovascular Events with continued aspirin use after lower gastrointestinal hemorrhage[J]. Gastroenterology, 2017, 152(3):669-670.

改良抗血小板药物方案在血小板高反应性未破裂颅内动脉瘤患者介入栓塞中的疗效及安全性

Efficacy and safety of modified antiplatelet preparation in patients with high on-treatment platelet reactivity after endovascular coiling for unruptured intracranial aneurysms

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	罗炯, 孙丛丛, 潘伟刚, 王丹, 史晓宁, 王茜, 金文青, 梁立荣, 杨春林, 马辛, 任艳萍. 经颅交流电刺激联合抗抑郁药对抑郁发作的疗效及安全性[J]. 首都医科大学学报, 2022, 43(2): 244-248.
[2]	任艳萍, 张俊岩, 吴涵, 罗炯, 杨春林, 马辛, 姜玮. 磁惊厥治疗与无抽搐电痉挛治疗抑郁发作的早期疗效及对认知功能的影响[J]. 首都医科大学学报, 2022, 43(2): 239-243.
[3]	李莉, 刘超猛, 任艳萍, 杨春林, 马辛. 改良电休克治疗首发精神分裂症的研究进展[J]. 首都医科大学学报, 2022, 43(2): 249-253.
[4]	孙昊, 郑美丽, 郭宗生, 张智勇, 李晓涛. 左心室收缩功能对经皮冠状动脉介入治疗的急性下壁ST段抬高型心肌梗死患者预后的影响[J]. 首都医科大学学报, 2022, 43(2): 305-310.
[5]	何振, 刘娟, 冀明, 李鹏, 张澍田. 内镜下黏膜剥离术治疗累及肛门齿状线直肠病变的临床效果评价[J]. 首都医科大学学报, 2022, 43(1): 38-41.
[6]	朱平, 禹环, 符丽梅, 廖欣, 熊暮珺, 雷阿明, 祝平安, 梁欣荃. 脐血移植治疗难治复发急性白血病的临床分析[J]. 首都医科大学学报, 2021, 42(6): 1041-1045.
[7]	姚懿, 唐晓芳, 宋莹, 姜琳, 乔树宾, 袁晋青. 急性冠状动脉综合征患者抗血小板药物抵抗的影响因素分析[J]. 首都医科大学学报, 2021, 42(5): 799-803.
[8]	程姣姣, 阮祥燕, 杜娟, 金凤羽, 李扬璐, 谷牧青. 卵巢组织冻存移植安全性的研究进展[J]. 首都医科大学学报, 2021, 42(4): 505-510.
[9]	鄢丹. 临床生物特征谱学:中药质量与临床合理用药评价——鄢丹教授[J]. 首都医科大学学报, 2020, 41(5): 773-777.
[10]	许晓晗, 程宇婧, 刘晓丽, 周玉杰. 守护生命的“心”路——周玉杰教授[J]. 首都医科大学学报, 2020, 41(5): 844-848.
[11]	房达, 赵乾, 杜宁, 赵隶嬴, 马良, 崔石昌. 肝癌放射介入治疗患者辐射剂量的分析[J]. 首都医科大学学报, 2020, 41(3): 454-457.
[12]	余英, 高峰, 张杰. 反流性食管炎治疗效果与食管下段菌群构成变化的关系研究[J]. 首都医科大学学报, 2020, 41(2): 243-248.
[13]	国家卫生健康委脑卒中防治工程专家委员会, 国家卫生健康委脑卒中防治工程委员会医院管理委员会, 国家卫生健康委脑卒中防治工程专家委员会急诊专业委员会. 新型冠状病毒肺炎疫情时期脑卒中绿色通道管理专家共识[J]. 首都医科大学学报, 2020, 41(2): 293-297.
[14]	郝鹏, 冯斯婷, 甄雷, 王晓, 王春梅, 聂绍平. SYNTAX II评分对急性ST段抬高型心肌梗死患者直接PCI术后无复流的预测价值[J]. 首都医科大学学报, 2019, 40(5): 744-748.
[15]	王希思, 杨维, 黄程, 赵文, 赵倩, 段超, 苏雁, 金眉, 张大伟, 秦红, 王焕民, 马晓莉. 儿童肝母细胞瘤的临床特征和治疗效果评价[J]. 首都医科大学学报, 2019, 40(2): 169-173.